Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD

Respiratory Medicine

Volumn 107, Issue 10, 2013, Pages 1538-1546

  Donohue, J F ^a   Maleki Yazdi, M R ^b   Kilbride, S ^c   Mehta, R ^d   Kalberg, C ^d   Church, A ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

agonist; COPD; Fixed dose combination; Long acting bronchodilator; Muscarinic antagonist; Randomised

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; VILANTEROL;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRY POWDER INHALER; ELECTROCARDIOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; HEMATOLOGICAL PROCEDURE; HOLTER MONITORING; HUMAN; LABORATORY TEST; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SHORTNESS OF BREATH WITH DAILY ACTIVITY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYMPTOM; TRANSITION DYSPNOEA INDEX; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN;

COPD; FIXED-DOSE COMBINATION; LONG-ACTING BRONCHODILATOR; MUSCARINIC ANTAGONIST; RANDOMISED; Β-AGONIST;

AGED; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINUCLIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84884816874     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.06.001     Document Type: Article

References (31)

1. B.R. Celli, W. MacNee ATS/ERS Task Force Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur Respir J 23 2004 932 946
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, revised 2011. http://www.goldcopd.org/uploads/users/files/GOLD-Report- 2011-Feb21.pdf [accessed 13.08.12].
3. V. Brusasco Reducing cholinergic constriction: the major reversible mechanism in COPD Eur Respri Rev 15 2006 32 36
4. M. Cazzola, and M. Molimard The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD Pulm Pharmacol Ther 23 2010 257 267
5. B. van de Maele, L.M. Fabbri, C. Martin, R. Horton, M. Dolker, and T. Overend Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients COPD 7 2010 418 427
6. T. van der Molen, and M. Cazzola Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes Prim Care Respir J 21 2012 101 108
7. F. Maltais, E. Beck, D. Webster, M.R. Maleki-Yazdi, J.V. Seibt, and A. Arnoux Four weeks once daily treatment with tiotropium + olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients Eur Respir J 36 Suppl. 54 2010 5557
8. J.A. van Noord, R. Buhl, C. Laforce, C. Martin, F. Jones, and M. Dolker QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease Thorax 65 2010 1086 1091
9. ® in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Am J Respir Crit Care Med 185 2012 A2259
10. C. Reisner, E. St Rose, S. Strom, T. Fischer, M. Golden, and M. Thomas Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD (P879) Eur Respir J 38 Suppl. 55 2011 150s
11. D.A. Mahler, A. D'Urzo, E.D. Bateman, S.A. Ozkan, T. White, and C. Peckitt Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison Thorax 67 2012 781 788
12. J.F. Donohue, A. Anzueto, J. Brooks, R. Mehta, C. Kalberg, and G. Crater A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD Respir Med 106 2012 970 979
13. N.A. Hanania, G. Feldman, W. Zachgo, J.J. Shim, C. Crim, and L. Sanford The efficacy and safety of the novel long-acting β2 agonist vilanterol in COPD patients: a randomized placebo-controlled trial Chest 142 2012 119 127
14. J.L. Hankinson, S.M. Kawut, E. Shahar, L.J. Smith, K.H. Stukovsky, and R.G. Barr Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study Chest 137 2010 138 145
15. J.L. Hankinson, J.R. Odencrantz, and K.B. Fedan Spirometric reference values from a sample of the general U.S. population Am J Respir Crit Care Med 159 1999 179 187
16. E.D. Manali, P. Lyberopoulos, C. Triantafillidou, L.F. Kolilekas, C. Sotiropoulou, and J. Milic-Emili MRC chronic dyspnea scale: relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study BMC Pulm Med 10 2010 32
17. M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, and A. Coates Standardisation of spirometry Eur Respir J 26 2005 319 338
18. D.A. Mahler, D.H. Weinberg, C.K. Wells, and A.R. Feinstein The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes Chest 85 1984 751 758
19. K. Howard, P. Berry, J. Petrillo, I. Wiklund, L. Roberts, and M. Watkins Development of the shortness of breath with daily activities questionnaire (SOBDA) Value Health 15 2012 1042 1050
20. P.W. Jones St. George's respiratory questionnaire: MCID COPD 2 2005 75 79
21. D.A. Mahler, and T.J. Witek Jr. The MCID of the transition dyspnea index is a total score of one unit COPD 2 2005 99 103
22. J.F. Donohue Minimal clinically important differences in COPD lung function COPD 2 2005 111 124
23. D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, and S. Menjoge A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
24. P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, and P.W. Jones Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789
25. Novartis. Indacaterol prescribing information. http://www.pharma.us. novartis.com/product/pi/pdf/arcapta.pdf [accessed 15.08.12].
26. GlaxoSmithKline. Salmeterol prescribing information. http://us.gsk.com/ products/assets/us-serevent-diskus.pdf [accessed 15.08.12].
27. Boehringer-Ingelheim. Tiotropium prescribing information. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing+Information/PIs/Spiriva/Spiriva.pdf [accessed 15.08.12].
28. G. Feldman, R.R. Walker, J. Brooks, R. Mehta, and G. Crater Safety and tolerability of the GSK573719/vilanterol combination in patients with COPD Am J Respir Crit Care Med 185 2012 A2938
29. M. Decramer, F. Maltais, G. Feldman, J. Brooks, S. Harris, and R. Mehta Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients Respir Physiol Neurobiol 185 2013 393 399
30. J. Lötvall, E.D. Bateman, E.R. Bleecker, W.W. Busse, A. Woodcock, and R. Follows 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids Eur Respir J 40 2012 570 579
31. GlaxoSmithKline. Salbutamol prescribing information. Available at: http://us.gsk.com/products/assets/us-ventolin-hfa.pdf/ [accessed February 2013].